Parabilis Medicines, Inc.(PBLS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Parabilis Medicines, Inc. (PBLS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PBLS is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Parabilis Medicines, Inc. reports quarterly revenue of $148.0K, net income of $-52.5M. Top institutional holders of PBLS by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., FMR, ARCH Venture Management, based on the most recent SEC filings. PBLS trades on the Nasdaq exchange and files with the SEC under CIK 1657677. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PBLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Parabilis Medicines, Inc. directly from SEC EDGAR.

Revenue

$148.0K

Net Income

$-52.5M

Institutions holding PBLS

Institutional investors reporting a position in Parabilis Medicines, Inc. on SEC Form 13F.
InstitutionSharesValueReported
RA CAPITAL MANAGEMENT, L.P.28,933,371$791.9M2026-06-30
FMR10,292,735$281.7M2026-06-30
ARCH Venture Management6,412,780$175.5M2026-06-30
venBio Partners5,266,697$144.1M2026-06-30
Alphabet4,919,498$134.6M2026-06-30
Nextech Invest, Ltd.4,663,176$127.6M2026-06-30
Cormorant Asset Management4,615,612$126.3M2026-06-30
REGENERON PHARMACEUTICALS4,166,666$114.0M2026-06-30
Siren, L.L.C.2,992,259$81.9M2026-06-30
FARALLON CAPITAL MANAGEMENT2,368,200$64.8M2026-06-30
SEC EDGAR: CIK 1657677 →
PBLS

Parabilis Medicines, Inc.

PBLS
NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q2 2026
EDGAR

$148.0K

Net Income

Q2 2026
EDGAR

$-52.46M

EPS (Diluted)

Q2 2026
EDGAR

$-2.32

ROIC

Q2 2026
EDGAR

-19.1%

Debt/Equity

Q2 2026
EDGAR

0.02

Top Institutional Holders

as of Q2 2026
$2.71B total
RA CAPITAL MANAGEMENT, L.P.
$791.91M--
FMR LLC
$281.71M--
ARCH Venture Management, LLC
$175.52M--
venBio Partners LLC
$144.15M--
Alphabet Inc.
$134.65M--
Nextech Invest, Ltd.
$127.63M--
Cormorant Asset Management, LP
$126.33M--
REGENERON PHARMACEUTICALS, INC.
$114.04M--
Siren, L.L.C.
$81.90M--
FARALLON CAPITAL MANAGEMENT LLC
$64.82M--

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…